Recursion Pharma Files 8-K/A Amendment
Ticker: RXRX · Form: 8-K/A · Filed: Nov 27, 2024 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | 8-K/A |
| Filed Date | Nov 27, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-reporting, exhibits
Related Tickers: RXRX
TL;DR
Recursion Pharma just amended its 8-K filing, likely updating financial info. Keep an eye on this.
AI Summary
Recursion Pharmaceuticals, Inc. filed an amendment (8-K/A) on November 27, 2024, to its previous report dated November 19, 2024. This amendment pertains to financial statements and exhibits, indicating a supplementary filing related to the company's financial reporting or disclosures.
Why It Matters
This filing is an amendment to a previous report, suggesting updated or corrected information is being provided by Recursion Pharmaceuticals, Inc. regarding its financial statements or exhibits.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, primarily concerning financial statements and exhibits, and does not appear to disclose new material events.
Key Players & Entities
- Recursion Pharmaceuticals, Inc. (company) — Registrant
- November 19, 2024 (date) — Date of earliest event reported
- November 27, 2024 (date) — Date of report and filing
- 41 S Rio Grande Street, Salt Lake City, UT 84101 (address) — Principal executive offices
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing serves as an amendment to a previous report, specifically addressing financial statements and exhibits.
When was the original event reported?
The earliest event reported was on November 19, 2024.
When was this amendment filed?
This amendment was filed on November 27, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 41 S Rio Grande Street, Salt Lake City, UT 84101.
What is the company's state of incorporation?
Recursion Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 818 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2024-11-27 16:09:08
Key Financial Figures
- $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar
Filing Documents
- rxrx-20241119.htm (8-K/A) — 26KB
- exhibit991-proformadraft11.htm (EX-99.1) — 422KB
- 0001601830-24-000229.txt ( ) — 602KB
- rxrx-20241119.xsd (EX-101.SCH) — 2KB
- rxrx-20241119_lab.xml (EX-101.LAB) — 21KB
- rxrx-20241119_pre.xml (EX-101.PRE) — 12KB
- rxrx-20241119_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (a) Pro forma financial information The unaudited pro forma condensed combined balance sheet of Recursion as of September 30, 2024, which combines the unaudited condensed consolidated balance sheets of Recursion and Exscientia as of September 30, 2024 and gives effect to the Transaction as if it occurred on September 30, 2024, and the unaudited pro forma condensed combined statements of operation of Recursion and Exscientia for the year ended December 31, 2023, and the nine months ended September 30, 2024, which combines the historical results of Recursion and Exscientia for the year ended December 31, 2023 and the nine months ended September 30, 2024 and gives effect to the Transaction as if it occurred on January 1, 2023, and the notes related thereto are filed as Exhibit 99.1 hereto and incorporated by reference herein. Exhibit Number Description 99.1 Unaudited pro forma condensed combined balance sheet of Recursion as of September 30, 2024 and the unaudited pro forma condensed combined statements of income of Recursion for the year ended December 31, 2023 and the nine months ended September 30, 2024, and the notes related thereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on November 20, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Christopher Gibson Christopher Gibson Chief Executive Officer